The Antidiabetic Drug Metformin Inhibits Gastric Cancer Cell Proliferation In Vitro and In Vivo

Kiyohito Kato1, Jian Gong1, Hisakazu Iwama5, Akira Kitanaka2, Joji Tani1, Hisaaki Miyoshi1, Kei Nomura1, Shima Mimura1, Mitsuyoshi Kobayashi1, Yuuichi Aritomo1, Hideyuki Kobara1, Hirohito Mor1, Takashi Himoto3, Keichi Okano4, Yasuyuki Suzuki4, Koji Murao2, and Tsutomu Masaki1

Abstract

Recent studies suggest that metformin, which is commonly used as an oral anti-hyperglycemic agent of the biguanide family, may reduce cancer risk and improve prognosis, but the mechanisms by which metformin affects various cancers, including gastric cancer, remains unknown. The goal of the present study was to evaluate the effects of metformin on human gastric cancer cell proliferation in vitro and in vivo and to study microRNAs (miRNA) associated with antitumor effect of metformin. We used MKN1, MKN45, and MKN74 human gastric cancer cell lines to study the effects of metformin on human gastric cancer cells. Athymic nude mice bearing xenograft tumors were treated with or without metformin. Tumor growth was recorded after 4 weeks, and the expression of cell-cycle-related proteins was determined. In addition, we used miRNA array tips to explore the differences among miRNAs in MKN74 cells bearing xenograft tumors treated with or without metformin in vitro and in vivo. Metformin inhibited the proliferation of MKN1, MKN45, and MKN74 in vitro. Metformin blocked the cell cycle in G0–G1 in vitro and in vivo. This blockade was accompanied by a strong decrease of G1 cyclins, especially in cyclin D1, cyclin-dependent kinase (Cdk) 4, Cdk6 and by a decrease in retinoblastoma protein (Rb) phosphorylation. In addition, metformin reduced the phosphorylation of epidermal growth factor receptor and insulin-like growth factor-1 receptor in vitro and in vivo. The miRNA expression was markedly altered with the treatment of metformin in vitro and in vivo. Various miRNAs altered by metformin also may contribute to tumor growth in vitro and in vivo. Mol Cancer Ther; 11(3); 549–60. ©2012 AACR.

Introduction

Gastric cancer is now the second-leading cause of cancer-related mortality worldwide, and the prognosis of advanced gastric cancer is poor (1). Apart from potentially curative surgery, chemotherapy and radiochemotherapy may be applied at advanced stages of gastric cancer but neither of these can be curative (2). Thus, there is a strong demand for new curative approaches to advanced gastric cancer.

Metformin is an oral biguanide drug introduced into clinical practice in the 1950s for the treatment of type 2 diabetes (3). It lowers hyperglycemia by inhibiting hepatic glucose production. According to a recent epidemiologic survey, metformin has significant effects on tumorigenesis. For instance, it is reported that patients with type 2 diabetes who are prescribed metformin have a lower risk of pancreatic cancer than patients who do not take metformin (4). In the basic investigations, metformin inhibited the proliferation of various human cancer cell types, such as those of prostate (5), breast (6), colon (7) and glial cancer (8). Metformin also inhibited tumor growth in prostate cancer (5) and breast cancer (9) in a mouse xenograft model. Furthermore, in a cancer animal model, metformin treatment decreased the incidence and size of mammary adenocarcinomas in Her2/Neu mice and prevented carcinogen-induced pancreatic cancer in hamsters (10). However, the mechanism underlying the suppression of cancer growth by metformin remains relatively unknown.

Here, we have shown that metformin inhibits the growth of gastric cancer by reducing cyclin D1, cyclin-dependent kinase (Cdk) 4, Cdk6. In addition, we have identified microRNAs (miRNA) associated with the antitumor effect of metformin.

Materials and Methods

Chemicals

Metformin (1,1-dimethylbiguanide monohydrochloride) was purchased from Dainippon Sumitomo Pharma.
A Cell Counting Kit (CCK-8) was purchased from Dojindo Laboratories, and all other chemicals were obtained from Sigma Chemical.

**Antibodies**

In this study, the following antibodies were used: anti-β-actin monoclonal antibody (Sigma-Aldrich; A5441, used at 1:3,000), cyclin D1 (Thermo Fisher Scientific; RB-9041, used at 1:1,000), cyclin E (BD Biosciences; used at 1:1,000), Cdk6 (Santa Cruz Biotechnology; sc-177, used at 1:1,000), Cdk4 (Cell Signaling Technology; #2906, used at 1:1,000), Cdk2 (Santa Cruz Biotechnology; sc-163, used at 1:2,000), phosphorylated retinoblastoma (Rb; BD Pharmingen; 558385, used at 1:1,000), Rb (Cell Signaling Technology; #9309, used at 1:1,000), and secondary horseradish peroxidase (HRP)-linked antimouse and antirabbit IgG antibodies (GE Healthcare UK; used at 1:2,000).

**Cell lines and culture**

The human gastric cancer cell lines MKN1, MKN45, and MKN74 were obtained from the Japanese Cancer Research Resources Bank and passaged in our laboratory for fewer than 6 months. The cell lines were authenticated by the cell bank using short tandem repeat PCR. Cells were grown in RPMI-1640 (Gibco Invitrogen) supplemented with 10% FBS (533-69545; Wako), and penicillin-streptomycin (100 mg/L; Invitrogen) in a humidified atmosphere of 5% CO2 at 37°C.

**Cell proliferation assay**

Cell proliferation assays were conducted using the CCK-8 according to the manufacturer’s instructions. Each cell line (1 × 10^5) was seeded into a well of a 96-well plate and cultured in 100 μL of RPMI-1640 supplemented with 10% FBS. After 24 hours, seeding cells were treated with 1, 5, and 10 mmol/L metformin and without metformin into 10% FBS. After 24 hours, seeding cells were treated with 1, 5, 10 mmol/L metformin and without metformin for 24 to 72 hours. After treatment, the cells were harvested and fixed in 80% ethanol. The fixed cells were washed with PBS and then stored at −20°C until flow cytometric analysis was conducted. On the day of analysis, cells were washed and centrifuged using cold PBS, suspended in 100 μL PBS and 10 μL RNase A solution (250 μg/mL) followed by incubation for 30 minutes at 37°C. Then, 110 μL propidium iodide (PI) stain (100 μg/mL) was added to each tube, which was then incubated at 4°C for at least 30 minutes prior to analysis. Flow cytometric analysis was conducted using a Cytomics FC 500 flow cytometer (Beckman Coulter) appointed with an argon laser (488 nm). The percentages of cells in different phases of the cell cycle were analyzed by using FlowJo software (Tree Star). All experiments were carried out in triplicate to assess for consistency of response.

**Xenograft model analysis**

Animal experiments were carried out according to the guidelines of the Committee on Experimental Animals of Kagawa University, Kagawa, Japan. We purchased 30 male athymic mice (BALB/c-ν/ν; 8 weeks old; 20–25 g) from Japan SLC Inc. The animals were maintained under specific pathogen-free conditions using a laminar airflow and had continuous free access to sterilized food (γ-ray-irradiated food, CL-2; CLEA Japan Inc.) and autoclaved water. Each mouse was inoculated with MKN74 cells (5 × 10^6 cells per animal) subcutaneously on the flank regions of the mouse. Two weeks later, the xenografts were identifiable as a mass of more than 6 mm in maximal diameter in all recipients. The animals were randomly assigned to 3 groups. These groups were treated with 1 mg metformin, 2 mg metformin, or control (PBS only), respectively.

The metformin-treated group was injected 5 times a week intraperitoneally (i.p.) at 1 mg/body or 2 mg/body per day for 4 weeks. Only PBS was administered to the control group (n = 10) for 4 weeks. After the initiation of the metformin administration, the tumor growth was monitored by the same investigators (K. Kato and T. Masaki), and the tumorigenesis of gastric cancer was monitored every day. Tumor size was measured weekly by measuring the 2 greatest perpendicular tumor dimensions. To examine the significance of the differences between growth curves in this study, all the measurements of tumor volume for each growth curve from the start of the treatment to the end, typically about 30 observations, were analyzed by one-way ANOVA. Tumor volume was calculated as follows: tumor volume (mm^3)
RNA samples typically showed a ratio of 260/280 of between 1.9 and 2.1, using an Agilent 2100 Bioanalyzer (Agilent Technologies). The density of the immunoreactive band obtained on the p-RTK array was analyzed by densitometric scanning (Tlc scanner, Shimizu Co., Ltd.). The unbound HRP antibody was washed out with TBS including 0.1% Tween-20. Finally, each array membrane was exposed to X-ray film using a chemiluminescence detection system (Perkin Elmer Co.).

**Antibody arrays of phosphorylated receptor tyrosine kinase**

RayBio Human Phospho Array Kit (catalog no. ARY 001) was purchased from RayBiotech, Inc. An assay for phosphorylated receptor tyrosine kinase (p-RTK) array was conducted according to the manufacturer's instructions. Briefly, p-RTK array membranes were blocked with 5% bovine serum albumin (BSA)/TBS (0.01 mol/L Tris-HCl, pH 7.6) for 1 hour. The membranes were then incubated with 2 mL of lysate prepared from cell lines or tumorous tissues after normalization with equal amounts of protein. After extensive washing with TBS including 0.1% Tween-20, 3 times for 10 minutes each, and TBS alone, twice for 10 minutes each, to remove unbound materials, the membranes were then incubated with anti-phospho-tyrosine-HRP antibody for 2 hours at room temperature. The unbound HRP antibody was washed out with TBS including 0.1% Tween-20. Finally, each array membrane was exposed to X-ray film using a chemiluminescence detection system (Perkin Elmer Co.). The density of the immunoreactive band obtained on the p-RTK array was analyzed by densitometric scanning (Tlc scanner, Shimizu Co., Ltd.).

**Analysis of miRNA microarray**

The samples of tumor and cancer cell lines were processed for total RNA extraction with the miRNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. RNA samples typically showed \( A_{260}/A_{280} \) ratios of between 1.9 and 2.1, using an Agilent 2100 Bioanalyzer (Agilent Technologies).

After RNA measurement with an RNA 6000 Nano kit (Agilent Technologies), the samples were labeled using a miRCURY Hy3/Hy5 Power Labeling Kit and were hybridized on a human miRNA Oligo chip (v.14.0; Toray Industries). Scanning was conducted with the 3D-Gen Scanner 3000 (Toray Industries). 3D-Gen extraction version 1.2 software (Toray Industries) was used to read the raw intensity of the image. To determine the change in miRNA expression between metformin-treated and control samples, the raw data were analyzed via GeneSpringGX v 10.0 (Agilent Technologies). Samples were first normalized relative to 28sRNA and baseline corrected to the median of all samples.

Replicate data were consolidated into 2 groups: those from metformin-treated animals and those from control animals and were organized by using the hierarchical clustering and ANOVA functions in the GeneSpring software. Hierarchical clustering was done by the use of the clustering function (condition tree) and Euclidean correlation as a distance metric. Two-way ANOVA analysis and asymptotic \( P \) value computation without any error correction on the samples were conducted to search for the miRNAs that varied most prominently across the different groups. The \( P \) value cutoff was set to 0.05. Only changes >50% for at least one of the time points for each sample were considered significant. All the analyzed data were scaled by global normalization. The statistical significance of differentially expressed miRNAs was analyzed by Student t test.

**Statistical analysis**

All analyses were conducted using the computer-assisted JMP8.0 (SAS Institute). Paired analysis between the groups was conducted using the \( t \) test. A \( P \) value of 0.05 was considered to indicate a significant difference between groups.

**Results**

**Metformin inhibits the proliferation of human gastric cancer cell growth**

To evaluate the effect of the growth activity of metformin on human gastric cancer cells in vitro, we examined the effect of metformin on proliferation in 3 gastric cancer cell lines, MKN1, MKN45, and MKN74. Cells were grown in 10% FBS and treated with 1, 5, and 10 mmol/L metformin or, as a control, without metformin. The cell proliferation assay was conducted 3 days after the addition of the agents. As shown in Fig. 1A, metformin led to a dose-dependent and strong inhibition of cell proliferation in all gastric cancer cell lines, with 49%, 35%, and 51% decreases in the viability of MKN1, MKN45, and MKN74 cells, respectively, with 10 mmol/L metformin.

To discern the direct relationship between the decrease in cell viability and the inhibition of cell proliferation, we followed the course of proliferation over 3 days after the addition of metformin. Metformin (0, 1, 5, and 10 mmol/L) led to a decrease in cell proliferation in a dose- and time-dependent manner in all 3 cell lines tested (Fig. 1B). Together, the results show that metformin inhibits gastric cancer proliferation.

**Effects of metformin on cell-cycle-regulatory proteins in MKN74**

To study whether or not metformin affects the MKN74 cell cycle, Western blotting was used to examine the expression of various cell-cycle-related molecules in MKN74 with and without metformin treatment. Cells were treated with 10 mmol/L metformin or without metformin for 24 to 72 hours. The most remarkable change was the loss of cyclin D1, a key protein implicated in the transition of the G0–G1 phase. In short, the cyclin D1 level declined slightly at 24 hours after the addition of metformin and was no longer detectable at 48 and 72 hours (Fig. 2A). The level of phosphorylated Rb also decreased progressively in metformin-treated cells. As shown in Fig. 2A, we then studied the expression of other cell-cycle-related proteins (Cdk4, Cdk6, cyclin E, and Cdk2) implicated in the G0–G1 transition. Although Cdk6, the catalytic subunit of cyclin D1, was decreased at 48 and 72 hours after the addition of metformin, Cdk4 was slightly
Metformin inhibits tumor proliferation in vivo

To determine whether or not metformin could affect tumor growth in vivo, we injected nude mice subcutaneously with MKN74 cells. Metformin was injected daily intraperitoneally at 1 or 2 mg.

On the basis of the integrated values of the tumor growth curves, intraperitoneal administration of metformin led to the substantial inhibition of tumor growth, by 41% (1 mg/d) and 78% (2 mg/d; Fig. 3A and B, P = 0.0207, one-way ANOVA). These growth rates were significantly above those of the control (P < 0.01 and P < 0.004, respectively). In addition, 2 mg metformin treatment significantly inhibited tumor growth compared with 1 mg metformin-treated mice (P < 0.007). In this study, metformin exhibited no apparent changes in mice and did not affect their weight (data not shown). All animals were alive during the experiment.

To determine whether or not metformin also affects cell-cycle-regulatory protein levels in vitro, we analyzed protein expression using Western blotting in tumors obtained from the xenograft experiments. Metformin reduced significantly the levels of these proteins (phosphorylated Rb, cyclin D1, Cdk2, Cdk4, Cdk6, and cyclin E) in treated tumors compared with controls (Fig. 3C). On the other hand, total Rb was the same in cell line irrespective of metformin. These results suggest that, similar to the results of the in vitro observations (Fig. 2A), metformin decreases tumor growth by reducing cell-cycle-regulatory protein levels, resulting in G1 cell-cycle arrest.

decreased at 48 and 72 hours later. Cyclin E was unchanged at 24 hours after metformin treatment but was decreased at 48 and 72 hours after. The catalytic subunit of cyclin E, Cdk2, was also slightly decreased at 48 and 72 hours after the addition of metformin. The level of phosphorylated Rb also decreased progressively in metformin-treated cells. On the other hand, total Rb was the same in cell line irrespective of metformin treatment. These events were detected in other cancer cell lines, such as MKN1 and MKN45 (data not shown).

Next, to further investigate the inhibition of MKN74 cell proliferation in the presence of metformin, the cell-cycle progression was examined by flow cytometry. We treated proliferating MKN74 cells with 10 mmol/L metformin for different durations. After the addition of metformin, the cell-cycle progression was examined by flow cytometry. We treated proliferating MKN74 cells with 10 mmol/L metformin. The level of phosphorylated Rb also decreased progressively in metformin-treated cells. On the other hand, total Rb was the same in cell line irrespective of metformin treatment. These events were detected in other cancer cell lines, such as MKN1 and MKN45 (data not shown).

To determine whether or not metformin could affect tumor growth in vivo, we injected nude mice subcutaneously with MKN74 cells. Metformin was injected daily intraperitoneally at 1 or 2 mg.

On the basis of the integrated values of the tumor growth curves, intraperitoneal administration of metformin led to the substantial inhibition of tumor growth, by 41% (1 mg/d) and 78% (2 mg/d; Fig. 3A and B, P = 0.0207, one-way ANOVA). These growth rates were significantly above those of the control (P < 0.01 and P < 0.004, respectively). In addition, 2 mg metformin treatment significantly inhibited tumor growth compared with 1 mg metformin-treated mice (P < 0.007). In this study, metformin exhibited no apparent changes in mice and did not affect their weight (data not shown). All animals were alive during the experiment.

To determine whether or not metformin also affects cell-cycle-regulatory protein levels in vitro, we analyzed protein expression using Western blotting in tumors obtained from the xenograft experiments. Metformin reduced significantly the levels of these proteins (phosphorylated Rb, cyclin D1, Cdk2, Cdk4, Cdk6, and cyclin E) in treated tumors compared with controls (Fig. 3C). On the other hand, total Rb was the same in cell line irrespective of metformin. These results suggest that, similar to the results of the in vitro observations (Fig. 2A), metformin decreases tumor growth by reducing cell-cycle-regulatory protein levels, resulting in G1 cell-cycle arrest.

Figure 1. A, metformin inhibits the proliferation of cultured gastric cancer cells. MKN1, MKN45, and MKN74 were seeded in 96-well plates. After 24 hours, metformin (1, 5, and 10 mmol/L) was added to the culture medium. Two days after the addition of the agents, a CCK assay was conducted as described in Materials and Methods. The results are expressed as percentages of viable cells compared with control (0 mmol/L). The mean cell number from 3 independent cultures is shown. Error bars represent SD. Using Student t test, all treatments were significantly different from the control (P < 0.05). B, MKN1, MKN45, and MKN74 cells were seeded at 10,000 cells per well in a 96-well plate and the agents were added at time 0 hour. A viability assay was conducted daily from time 0 to 72 hours. The data points represent the mean cell number from 3 independent cultures, and the error bars represent SDs. For each cell line, the conditions at 48 and 72 hours are significantly different compared with the control (0 mmol/L), with P < 0.05.
Differences in p-RTKs in vitro and in vivo treated with and without metformin

We used a p-RTK array system to identify the "key RTKs" associated with the antitumor effect of metformin. By using the antibody array (Fig. 4A), we simultaneously screened the expressions of 42 different activated RTKs in MKN74 cells and tumors with or without metformin. Metformin reduced the expression of phosphorylated epidermal growth factor receptor (p-EGFR; Fig. 4B and D) and that of phosphorylated insulin-like growth factor-1 receptor (p-IGF-1R; Fig. 4C and D) in vitro and in vivo, as the protein array detected.

Densitometric data on p-EGFR and p-IGF-1R in cell line and tumorous tissue were expressed as black and white, respectively. The density of the p-EGFR and that of the p-IGF-1R obtained from the membrane array were analyzed by means of an Image Station (Eastman Kodak). The densitometric ratios of the p-EGFR and p-IGF-1R spots of the metformin-treated cell line to nontreated metformin were 68.8% and 4.0%, respectively (Fig. 4D). In addition, the ratios of p-EGFR and p-IGFR of metformin-treated tumorous tissue to nontreated metformin were 39.7% and 19.8%, respectively (Fig. 4D).

Differences in miRNA expression in the cell lines in vitro and tumorous tissues in vivo treated with and without metformin

Using a custom microarray platform, we analyzed the expression levels of 985 human miRNA probes in the cell lines in vitro and tumorous tissues in vivo that were treated with and without metformin. As shown Table 1, when the expression of miRNAs was studied in MKN74 cells treated with 10 mmol/L metformin and without metformin in vitro, 30 miRNAs were significantly upregulated (Table 1) in MKN74 cells after 72 hours of metformin treatment whereas 21 miRNAs were downregulated (Table 1). In a tumor xenograft model, in the metformin group, there were 22 upregulated (Table 2) and 21 downregulated miRNAs (Table 2) of the 985 miRNAs (GEO, accession no.GSE30289). In Tables 1 and 2, the 7 miRNAs marked with a dagger were matched with ones from both cultured cells and xenograft tissues after metformin treatment.

Unsupervised hierarchical clustering analysis, using Pearson’s correlation, showed that cell lines in vitro and tumorous tissues in vivo treated with metformin clustered together and separately from the untreated cell lines (Fig. 5A) and tissues (Fig. 5B). These subsets of 51 microRNAs in cell lines and 43 miRNAs in tissues were found to exhibit >1.5-fold alterations in expression levels between the metformin-treated and control groups.

Discussion

The incidence and mortality rate of gastric cancer have decreased dramatically over the past several decades. Nonetheless, the disease remains a major public health issue as the second-leading cause of cancer death worldwide (16). Apart from potentially curative surgery, chemotherapy and radiochemotherapy may be applied at advanced stages in gastric cancer but neither can cure the...
disease in such cases and the prognosis is poor. Thus, there is strong demand for new curative approaches to gastric cancer therapy.

The role of the antidiabetic drug metformin in glucose and fatty acid metabolism is very well known (17, 18). In mice, at doses of 1 to 3 mg/d, it stimulates glucose uptake and increases fatty acid oxidation in muscle and liver with no side effects (5). Recent data suggest that metformin could protect from cancer and inhibit proliferation in various cancer cell lines, such as breast (11), glioblastoma (9), and prostate cancer (5). However, the antitumor effect of metformin for gastric cancer remains unknown. Here, we show that metformin not only is a very potent inhibitor of human gastric cancer cell growth but also inhibits tumorigenesis in a xenograft model when administered intraperitoneally.

Specific cyclin/Cdk complexes are activated at different intervals during the cell cycle. Complexes of Cdk4 and Cdk6 with cyclin D1 are required for G1 phase progression, whereas complexes of Cdk2 with cyclin E are required for the G1-S transition (19). In previous reports, downregulation of cyclin D1 in response to metformin has been shown in various cancer cell lines, such as colon (7), breast (20), and prostate cancer (5). However, the effects of metformin on catalytic subunits of cyclin D1, Cdk4 and Cdk6, remain unknown. In the present study, the major cell-cycle regulators (cyclin D1, Cdk4, Cdk6, cyclin E, Cdk2, phosphorylated Rb) could be intracellular targets of the metformin-mediated antiproliferative effect in human gastric cancers in vitro. In addition, flow cytometry revealed that metformin arrested gastric cancer cells at the G0–G1 phase in vitro. A subsequent in vitro experiment using subcutaneous gastric cancer-bearing athymic nude mice also showed that metformin markedly suppressed the growth of gastric cancer, and the expression levels of numerous cell-cycle molecules (cyclin D1, Cdk4, Cdk6, cyclin E, Cdk2, phosphorylated Rb) were found to be reduced by treatment with metformin, indicating that metformin may inhibit the expression of cell-cycle-related proteins, especially in cyclin D1.

Our in vitro study was conducted using a higher dose of metformin than the human therapeutic concentration (6–30 μmol/L). The use of such higher doses has been the
Metformin Inhibits Gastric Cancer Cell Proliferation

Figure 4. A, template showing the location of tyrosine kinase antibody spotted onto the RayBio Human Phospho Array Kit. B and C, representative expression of various p-RTKs in gastric cancer cell lines and tumors with or without metformin (Met) treatment. The reduced expression levels of p-EGFR and p-IGF-1R were detected in metformin-treated cell lines and tumors. D, the densitometric ratios of the p-EGFR and p-IGF-1R spots of the metformin-treated cell line to the nontreated line were 68.8% and 4.0%, respectively. The ratios of p-EGFR and p-IGFR of metformin-treated tumorous tissue to nontreated tissue were 39.7% and 19.8%, respectively.

subject of criticism of similar studies in other cancer cell types, such as breast (6), prostate (5), and colon cancer cell lines (7). However, it is important to consider that cells in culture are grown under hyperglycemic conditions (21). Tissue culture medium alone contains high concentrations of glucose, and 5% to 10% FBS is typically added, resulting in excessive growth stimulation. This may explain why, to see the antitumor effects of metformin in cell culture systems, it is necessary to use higher doses than are used in patients with diabetes.

Many previous reports have shown the enhanced expression of various cell-cycle-related molecules (cyclin D1, Cdk4, Cdk6, cyclin E, and Cdk2) in various cancers, including gastric cancer (22, 23). Therefore, inhibition of these cell-cycle-related molecules, including cyclin D1, may be an interesting molecular target for controlling tumor proliferation.

Metformin leads to changes in the phosphorylation of various proteins. To date, the change in phosphorylation of various molecules, such as Akt, β-catenin, CREB, Chk2 (24), and c-Src (21), has been detected in cell lines treated with metformin. We also detected the reduction of p-EGFR and p-IGF-1R in gastric cancers with metformin treatment using protein arrays. These data suggest that the expression of p-EGFR and that of p-IGF-1R are reduced by metformin treatment in gastric cancer cells. Recently, some studies have also reported that metformin reduces the expression levels of p-EGFR and p-IGF-1R in breast cancer (21) and pancreatic cancer (25). Together, these studies suggest that metformin might reduce the expression levels of p-EGFR and p-IGF in many cancer types, including gastric cancer.

The EGFR pathway is important in controlling cell-cycle events. The role of EGFR activation in cell-cycle progression in some human cancers was studied. EGFR activation induced cyclin D1, a protein that is important in cell-cycle progression (26, 27). Like EGFR, IGF-R1 has been shown to regulate both the expression and activity of many proteins involved in cell-cycle progression (28, 29). In rat L6E9 skeletal muscle cells, IGF-1 activation is upregulated with the expression of Cdk4 and cyclin D1 (30). Therefore, metformin blocks the cell cycle in G0–G1 in vitro and in vivo through the reduction of EGFR and IGF-1R activity.

To identify miRNA associated with the antitumor effect of metformin, using miRNA expression arrays, we have determined variations in miRNA profiles in gastric cancer cell lines both in culture and in xenograft tumorous tissues treated with metformin compared with those not treated with metformin. The cluster analyses we conducted clearly showed that metformin treatment affects the extent of miRNA expression in cultured cells and in tumorous tissues. In the analyses, we selected sets of miRNAs that altered their expression levels significantly before and after metformin treatment. We identified 51 miRNAs differentially expressed (30 upregulated and 21 downregulated) in culture and 43 miRNAs differentially expressed (22 upregulated and 21 downregulated) in xenograft tumorous tissues. These miRNAs are meaningful candidates to gauge the effectiveness of metformin.
Table 1. Statistical results and chromosomal locations of miRNAs in MKN74 cells treated with metformin, compared with nontreated cells

<table>
<thead>
<tr>
<th>miRNA</th>
<th>Fold (treated/nontreated), mean/C6</th>
<th>SD</th>
<th>P</th>
<th>Chromosomal localization</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa-miR-638</td>
<td>3.31 ± 1.05</td>
<td>0.0083</td>
<td>19p13.2</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-1246</td>
<td>2.65 ± 1.12</td>
<td>0.0036</td>
<td>2q31.1</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-1228a</td>
<td>2.59 ± 1.56</td>
<td>0.0145</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-1469</td>
<td>2.55 ± 1.73</td>
<td>0.029</td>
<td>15q26.2</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-762</td>
<td>2.30 ± 0.25</td>
<td>0.0008</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-1268</td>
<td>2.24 ± 0.96</td>
<td>0.0248</td>
<td>15q11.2</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-1908</td>
<td>2.04 ± 0.87</td>
<td>0.0081</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-663</td>
<td>2.04 ± 0.72</td>
<td>0.0133</td>
<td>20p11.1</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-423-3p</td>
<td>2.01 ± 0.84</td>
<td>0.0186</td>
<td>17q11.2</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-31</td>
<td>1.79 ± 0.99</td>
<td>0.0367</td>
<td>9p21.3</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-1973</td>
<td>1.63 ± 0.70</td>
<td>0.0106</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-934</td>
<td>1.58 ± 0.53</td>
<td>0.0349</td>
<td>Xq26.3</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-27b</td>
<td>1.53 ± 0.56</td>
<td>0.0204</td>
<td>9q22.32</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-182</td>
<td>1.52 ± 0.45</td>
<td>0.0173</td>
<td>7q32.2</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-1977</td>
<td>1.51 ± 0.35</td>
<td>0.0003</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-149</td>
<td>1.48 ± 0.46</td>
<td>0.0026</td>
<td>2q37.3</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-129a-5p</td>
<td>1.48 ± 0.81</td>
<td>0.0353</td>
<td>18q13.41</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-27a</td>
<td>1.47 ± 0.42</td>
<td>0.0016</td>
<td>19p13.13</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-361-5p</td>
<td>1.47 ± 0.61</td>
<td>0.0477</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-200a</td>
<td>1.41 ± 0.33</td>
<td>0.0144</td>
<td>1p36.33</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-26b</td>
<td>1.40 ± 0.29</td>
<td>0.0039</td>
<td>2q35</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-22</td>
<td>1.39 ± 0.29</td>
<td>0.0018</td>
<td>17p13.3</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-24</td>
<td>1.35 ± 0.40</td>
<td>0.003</td>
<td>9q22.32</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-21</td>
<td>1.27 ± 0.17</td>
<td>0.0034</td>
<td>7q32.2</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-18a</td>
<td>1.25 ± 0.43</td>
<td>0.048</td>
<td>13q31.3</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-200c</td>
<td>1.23 ± 0.12</td>
<td>0.0012</td>
<td>12p13.3</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-7</td>
<td>1.17 ± 0.12</td>
<td>0.0047</td>
<td>9q22.32</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-1975</td>
<td>1.16 ± 0.21</td>
<td>0.0341</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-1826a</td>
<td>0.520 ± 0.166</td>
<td>0.0147</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-1979</td>
<td>0.621 ± 0.100</td>
<td>0.0002</td>
<td>4q32.3</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-1260a</td>
<td>0.630 ± 0.121</td>
<td>0.0009</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-30e</td>
<td>0.679 ± 0.229</td>
<td>0.0182</td>
<td>1p34.2</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-182a</td>
<td>0.682 ± 0.274</td>
<td>0.0045</td>
<td>7q32.2</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-422a</td>
<td>0.691 ± 0.245</td>
<td>0.0255</td>
<td>15q22.31</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-372</td>
<td>0.692 ± 0.226</td>
<td>0.0026</td>
<td>19q13.42</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-1280a</td>
<td>0.703 ± 0.197</td>
<td>0.0171</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-130b</td>
<td>0.708 ± 0.325</td>
<td>0.01</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-18b</td>
<td>0.716 ± 0.290</td>
<td>0.0086</td>
<td>Xq26.2</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-221</td>
<td>0.719 ± 0.224</td>
<td>0.0111</td>
<td>Xp11.3</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-320b</td>
<td>0.734 ± 0.215</td>
<td>0.014</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-320c</td>
<td>0.738 ± 0.301</td>
<td>0.0164</td>
<td>18q11.2</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-151-3p</td>
<td>0.751 ± 0.238</td>
<td>0.0178</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-1274b</td>
<td>0.759 ± 0.235</td>
<td>0.0316</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-7</td>
<td>0.771 ± 0.202</td>
<td>0.0152</td>
<td>9q21.32</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-30e</td>
<td>0.774 ± 0.171</td>
<td>0.02</td>
<td>1p34.2</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-24-2'</td>
<td>0.775 ± 0.253</td>
<td>0.0126</td>
<td>19p13.13</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-1274a</td>
<td>0.818 ± 0.156</td>
<td>0.0302</td>
<td>5p13.1</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-720</td>
<td>0.827 ± 0.196</td>
<td>0.0376</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>hsa-miR-23b</td>
<td>0.858 ± 0.240</td>
<td>0.0265</td>
<td>9q22.32</td>
<td></td>
</tr>
</tbody>
</table>

*MiRNAs that were matched to miRNAs extracted from cultured cells and tumorous tissues after treatment with metformin.
We found that members of the let-7 family are upregulated in both cultured cells and tumorous tissues treated with metformin. The human let-7 family...
containing 13 members is widely recognized as a class of miRNAs producing a tumor-suppressing effect (31). Consistent with this event, downregulation of let-7 family members has been reported in many cancers, such as lung (32), breast (33), colorectal cancer (34), and melanoma (35). The let-7 family acts as a tumor suppressor by binding its target oncogenes, including the Ras (36), HMGA2 (37), c-Myc (38), and various cell-cycle regulators. Among upregulated let-7 family members in cell culture in the present study, let-7b overexpression in melanoma cells in vitro leads to the downregulation of the expression of cyclins D1, D3 and A, as well as to the downregulation of Cdk 4 (35, 39). In addition, let-7g targets cell-cycle control genes such as cyclin D1, E2F1, Ras, and c-myc and restrains the growth of hepatoma cells (40). Thus, our results suggest that metformin-induced inhibition of human gastric cancer cell proliferation is mediated, in part, by the tumor suppressor activities caused by upregulation of let-7 family members.

We also found differentially expressed miRNAs in cultured cells and tumor tissues treated with metformin as compared with untreated cells. Among upregulated miRNAs in culture cells treated, hsa-mir-663 inhibits the growth of gastric cancer (41), hsa-mir-22 inhibits the growth of hepatocellular carcinoma (42), and hsa-mir-182 inhibits the growth of lung cancer (43). Especially, the expression of hsa-mir-638 in metformin-treated cells was 3.3 times higher than that in untreated cells. The hsa-mir-638 is one of the miRNAs most abundantly expressed in normal serum. Although the physiologic significance of hsa-mir-638 is not adequately known, one report shows decreased expression of hsa-mir-638 in gastric cancer tissues (44). Thus, our data suggest that hsa-mir-638 may be a candidate for a new therapeutic target in gastric cancer.

In the present study, we found only 7 matched miRNAs extracted from cultured cells and tumor tissues after treatment with metformin. Although many miRNAs were significantly altered after metformin treatment, we found several differences in the profiles of miRNA expression between the cultured cells and tumor tissues. This discrepancy could reflect the differences between in vitro and in vivo models. In short, metformin is directly exposed to in vitro cultured cells, whereas intraperitoneally administered metformin is metabolized in vivo. In addition, tumor cells in mice are affected by the host’s immune response. Furthermore, there are differences in exposure times and metformin concentrations between the in vitro and in vivo models. Therefore, differences in exposure times and concentrations of metformin
may result in the differential expression profiles of miRNAs. In conclusion, our results revealed that metformin inhibits human gastric cancer cell proliferation and tumor growth, possibly by suppressing the cell-cycle-related molecules via alteration of miRNAs. Metformin post-poned spontaneous carcinogenesis in mice and rats, as well as chemical and radiation carcinogenesis in mice, rats, and hamsters (45). In addition, in female SHR mice, metformin increased life span and postponed tumors when started at young or middle age but not when started at old age (46). These data suggest that metformin might be a more effective treatment for young patients with gastric cancer.

Metformin is a drug widely used for the treatment of type 2 diabetes with limited side effects. Therefore, metformin may become a novel and effective therapy for the treatment and long-term management of gastric cancer, providing additional benefits at low cost.

Supporting information available
Supplementary Data S1. This material is available free of charge via the Internet at http://www.microrna.org and http://www.ncbi.nlm.nih.gov/gene.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interests were disclosed.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 3, 2011; revised December 5, 2011; accepted December 19, 2011; published OnlineFirst January 5, 2012.

References
2. Lordick F, Siewert JR. Recent advances in multimodal treatment for gastric cancer: a review. Gastric Cancer 2005;8:78–85.


Molecular Cancer Therapeutics

The Antidiabetic Drug Metformin Inhibits Gastric Cancer Cell Proliferation *In Vitro* and *In Vivo*

Kiyohito Kato, Jian Gong, Hisakazu Iwama, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-11-0594

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2012/01/05/1535-7163.MCT-11-0594.DC1

Cited articles
This article cites 46 articles, 7 of which you can access for free at:
http://mct.aacrjournals.org/content/11/3/549.full#ref-list-1

Citing articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
http://mct.aacrjournals.org/content/11/3/549.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://mct.aacrjournals.org/content/11/3/549.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.